//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Merck and Gilead announce positive phase 3 topline results for islatravir/lenacapavir once-weekly single-tablet HIV drug. #IDsky #AIDS #virology #publichealth #pharma
1d
– Novel Investigational Combination Pairs Merck’s Islatravir, a Next-Generation Nucleoside Analog with Multiple Mechanisms of Action, including Translocation Inhibition, with Gilead’s Lenacapavir, a F...
www.merck.com
Gilead and Merck Announce Positive Topline Results from two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment - Merck.com
Alicia Ault